Chiara Gorrini

Dr. Chiara Gorrini

Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CRCecilia Roux
Cecilia Roux
SJSoode Moghadas Jafari
Soode Moghadas Jafari
RSRahul Shinde
Rahul Shinde
GDGordon Duncan
Gordon Duncan
DCDavid W. Cescon
David W. Cescon
CGChiara Gorrini
Chiara Gorrini
Significance: Immunotherapies targeting the programmed death-1 (PD-1) and its ligand PD-L1 have recently been combined with standard chemotherapy to potentiate the treatment of solid tumors, including triple negative breast cancer (TNBC). Reactive oxygen species (ROS) have been directly linked to the cytotoxic effects of chemotherapy. Here we report that ROS induced either by chemotherapy (paclitaxel) or antioxidant depletion induce PD-L1 expression in macrophages. PD-L1 positive macrophages have immune-suppressive and angiogenic properties that interfere with the efficacy of paclitaxel in vivo. Indeed, PD-L1 blockade reverts this effect and synergizes with paclitaxel to reduce tumor growth. Our work reveals a pathway that further supports the importance of combining taxane and PD-L1 inhibitors as promising anticancer strategy in TNBC.

7 February 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SKShawn P. Kubli
Shawn P. Kubli
CBChristian Bassi
Christian Bassi
CRCecilia Roux
Cecilia Roux
AWAndrew Wakeham
Andrew Wakeham
CGChristoph Göbl
Christoph Göbl
CGChiara Gorrini
Chiara Gorrini
Significance: Basal-like/BRCA1-associated breast cancer (BC) is a very aggressive form of BC that frequently occurs in young women, with devastating effects. Since tailored therapies are lacking for this type of tumor, scientists and clinicians are searching for weaknesses that can be therapeutically exploited. Here we describe the role of the transcription factor aryl hydrocarbon receptor (AhR) in supporting BC growth by controlling reactive oxygen species (ROS) levels and the tumor-promoting features of the microenvironment. In BC cells, AhR activation mediates the link between intracellular ROS regulation and the protumorigenic functions of the surrounding immune system. We propose that tailored inhibition of AhR-regulated pathways can lead to BC eradication by pushing it beyond its ROS tolerance limit and depriving it of tumor-supporting immune cells.